☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Shanghai Henlius Biotech
Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-...
February 6, 2024
Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Ca...
June 26, 2023
PharmaShots' Key Highlights of First Quarter 2023
April 3, 2023
Insights+ Key Biosimilars Events of February 2023
March 1, 2023
Shanghai Henlius Biotech Reports the First Patient Dosing of HLX15 (biosimilar, daratumumab) in P-I Clinical Trial for Multiple My...
February 3, 2023
Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the U...
November 30, 2022
Load more...
Back to Home